Listed

Cellectis S.A.: Form 20-F for the period ended Dec 31, 2025

Filed with the SEC on Mar 20, 2026 and accepted by EDGAR at Mar 19, 2026, 19:52 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2025-01-01 to 2025-12-31$72.9mifrs-full:Revenue
Cost of revenue12 months2025-01-01 to 2025-12-31$0ifrs-full:CostOfSales
Operating income12 months2025-01-01 to 2025-12-31−$33.1mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2025-01-01 to 2025-12-31−$423.0kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2025-01-01 to 2025-12-31−$67.6mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2025-01-01 to 2025-12-31−$0.67ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2025-01-01 to 2025-12-31−$0.67ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2025-01-01 to 2025-12-31−$39.4mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2025-01-01 to 2025-12-31$2.4mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2025-12-31$61.5mifrs-full:CashAndCashEquivalents
Total assetsAt period end2025-12-31$324.7mifrs-full:Assets
Current liabilitiesAt period end2025-12-31$145.8mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2025-12-31$248.8mifrs-full:Liabilities
Shareholders' equityAt period end2025-12-31$75.9mifrs-full:EquityAttributableToOwnersOfParent

Source: SEC EDGAR, the filing index for accession 0001193125-26-116428. Last ingested by Listed: Nov 14, 2026, 10:50 ET. Listed shows no prices and gives no investment advice.